BJDX news & sentiment — Bluejay Diagnostics, Inc.

MAY 19·Stock TitanMed

Bluejay Diagnostics (NASDAQ: BJDX) CEO adds 12,500 shares in private placement

Bluejay Diagnostics (NASDAQ: BJDX) President and CEO Indranil Dey purchased 12,500 shares of common stock at $2.00 per share in a private placement on March 14, 2026. This transaction increased his direct holdings to 12,522 shares, with an additional 127 shares held indirectly through Lana Management & Business Research International, LLC. The purchase, valued at $25,000, signals a positive sentiment from the CEO.

MAY 1·Stock Titan

Bluejay Diagnostics (NASDAQ: BJDX) seeks reverse split and major stock plan expansion

Bluejay Diagnostics (NASDAQ: BJDX) is requesting shareholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-20, aimed at maintaining its Nasdaq listing by increasing its stock price. The company also seeks to expand its 2021 Stock Plan by 600,000 shares to increase capacity for future equity awards. These proposals will be voted on at the annual meeting on June 9, 2026, alongside the election of five directors and the ratification of Wolf & Company, P.C. as the independent auditor.

NOV 10·Benzinga

Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships - Bluejay Diagnostics ( NASDAQ:BJDX )

Company focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization. Patient enrollment in SYMON-II clinical trial now approximately 50% completed. Recent private placement transaction completed in ...

$BJDX

Bluejay Diagnostics (NASDAQ: BJDX) CEO adds 12,500 shares in private placement

Bluejay Diagnostics (NASDAQ: BJDX) seeks reverse split and major stock plan expansion

Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships - Bluejay Diagnostics ( NASDAQ:BJDX )

News on $BJDX